RPTP = Top Management und Krass Unterbewertet !!! - 500 Beiträge pro Seite
eröffnet am 05.01.10 19:06:48 von
neuester Beitrag 25.07.11 17:06:55 von
neuester Beitrag 25.07.11 17:06:55 von
Beiträge: 48
ID: 1.155.154
ID: 1.155.154
Aufrufe heute: 0
Gesamt: 2.943
Gesamt: 2.943
Aktive User: 0
ISIN: US75382F1066 · WKN: A0YBWE
8,2500
EUR
-0,76 %
-0,0630 EUR
Letzter Kurs 27.10.16 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,5800 | +922,86 | |
| 1,0400 | +48,57 | |
| 0,5400 | +38,46 | |
| 1,9900 | +32,67 | |
| 5,4000 | +27,06 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,3400 | -34,63 | |
| 3,6400 | -38,62 | |
| 0,5660 | -40,42 | |
| 1,7700 | -46,69 | |
| 84,75 | -74,50 |
Feedback
Da ich nicht soviel Zeit habe hier ein kleiner Überblick
1) Top-Management von BioMarin ist hier am werk
2) Sehr aussichtsreiche Pipeline
3) Erstes Produkt wahrscheinlich schon in 2011 erhältlich
4) Partnerschaft mit Roche
5) PIII für DR Cysteamine-cystinosis startet im 1Q 2010
Hab 5000st zu 1,80$ gekauft .Die tage werde ich mehr über RPTP posten .
Raptor Pharma (RPTP)
Marktkap : 42 Mio$
Cash : 10,5 Mio$
Kurs : 1,88 $
Shares Out : 23 M
Raptor is at an inflection point in that they are soon to be a NASDAQ listed
company as a result of their pending merger with TorreyPines (expected to close in Q4 2009) and they will potentially have their cystinosis drug on the market in 1H 2011. The fact that Raptor is potentially 18 months away from producing revenues represents a significant opportunity for investors and why we believe Raptor’s share price will increase substantially from current levels.Raptor currently has a balanced pipeline of clinical and preclinical programs.
The Company is currently involved in four Phase II clinical programs.The Company’s clinical trials address indications representing large markets worldwide: ALDH2 deficiency and NASH; along with Orphan Indications which typically have a shorter development cycle: cystinosis, and Huntington’s Disease. ALDH2 deficiency and Huntington’s Disease each represent potentially
billion dollar markets.
Collaboration with Roche on therapeutic delivery across
blood-brain barrier to potentially treat neurodegenerative
diseases
• First NDA filing to FDA expected in 2010 (cystinosis)
• Clinical-stage programs:
o DR Cysteamine-cystinosis (Phase IIb)
o DR Cysteamine- non-alcoholic steatohepat
or NASH (Phase IIa)
o DR Cysteamine- Huntington’s Disease (Phase II)
o Convivia™- ALDH2 Deficiency (Phase IIa)
• Positive results from the Phase IIa trial of Convivia™ to
address ALDH2 deficiency
• Lead preclinical product candidate, receptor
protein (“RAP”), a drug delivery platform technology, could
deliver various drugs to treat multiple indications, including
HCC and HCV
1) Top-Management von BioMarin ist hier am werk
2) Sehr aussichtsreiche Pipeline
3) Erstes Produkt wahrscheinlich schon in 2011 erhältlich
4) Partnerschaft mit Roche
5) PIII für DR Cysteamine-cystinosis startet im 1Q 2010
Hab 5000st zu 1,80$ gekauft .Die tage werde ich mehr über RPTP posten .
Raptor Pharma (RPTP)
Marktkap : 42 Mio$
Cash : 10,5 Mio$
Kurs : 1,88 $
Shares Out : 23 M
Raptor is at an inflection point in that they are soon to be a NASDAQ listed
company as a result of their pending merger with TorreyPines (expected to close in Q4 2009) and they will potentially have their cystinosis drug on the market in 1H 2011. The fact that Raptor is potentially 18 months away from producing revenues represents a significant opportunity for investors and why we believe Raptor’s share price will increase substantially from current levels.Raptor currently has a balanced pipeline of clinical and preclinical programs.
The Company is currently involved in four Phase II clinical programs.The Company’s clinical trials address indications representing large markets worldwide: ALDH2 deficiency and NASH; along with Orphan Indications which typically have a shorter development cycle: cystinosis, and Huntington’s Disease. ALDH2 deficiency and Huntington’s Disease each represent potentially
billion dollar markets.
Collaboration with Roche on therapeutic delivery across
blood-brain barrier to potentially treat neurodegenerative
diseases
• First NDA filing to FDA expected in 2010 (cystinosis)
• Clinical-stage programs:
o DR Cysteamine-cystinosis (Phase IIb)
o DR Cysteamine- non-alcoholic steatohepat
or NASH (Phase IIa)
o DR Cysteamine- Huntington’s Disease (Phase II)
o Convivia™- ALDH2 Deficiency (Phase IIa)
• Positive results from the Phase IIa trial of Convivia™ to
address ALDH2 deficiency
• Lead preclinical product candidate, receptor
protein (“RAP”), a drug delivery platform technology, could
deliver various drugs to treat multiple indications, including
HCC and HCV
Kapitalerhöhung wurde erst vor wenigen tagen abgeschlossen .Ich denke es wird schon sehr bald über 2$ gehen .
Gehts vielleicht heute schon über 2$ ????
http://ir.raptorpharma.com/phoenix.zhtml?c=198466&p=irol-IRH…
http://ir.raptorpharma.com/phoenix.zhtml?c=198466&p=irol-IRH…
Volumen ist in den letzten zwei Handelstagen gestiegen vielleicht hat das mit den zwei Studienergebnisse zu tun die schon überfällig sind .
Raptor hat einiges im 1Q zu berichten ...
WntTideTM (Breast Cancer) Preclinical (ongoing) data to publish Q4 2009
DR Cysteamine Non-Alcoholic Steatohepatitis ("NASH") Phase IIa (ongoing, open IND), data Q4 09 <<< PIIa Interimsdaten waren positiv
DR Cysteamine Nephropathic Cystinosis (“Cystinosis”) Phase IIa (ongoing, open IND) Orphan Drug Designation, IIb ongoing, Phase III Q1 2010
DR Cysteamine Huntington’s Disease ("HD") Phase II (planned Q1 2010) Orphan Drug Designation
Raptor hat einiges im 1Q zu berichten ...
WntTideTM (Breast Cancer) Preclinical (ongoing) data to publish Q4 2009
DR Cysteamine Non-Alcoholic Steatohepatitis ("NASH") Phase IIa (ongoing, open IND), data Q4 09 <<< PIIa Interimsdaten waren positiv
DR Cysteamine Nephropathic Cystinosis (“Cystinosis”) Phase IIa (ongoing, open IND) Orphan Drug Designation, IIb ongoing, Phase III Q1 2010
DR Cysteamine Huntington’s Disease ("HD") Phase II (planned Q1 2010) Orphan Drug Designation
Trading Spotlight
Hier kann man die News wahlweise auf Deutsch o. Englisch lesen.....
http://www.finanznachrichten.de/nachrichten-aktien/raptor-ph…
http://www.finanznachrichten.de/nachrichten-aktien/raptor-ph…
Raptor Pharmaceutical Corp. (RPTP)
Target Price: $6.56 <<< Kursziel von Vista (ende Nov 2009)
Raptor announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.S. population.
the completion of the initial six-month treatment phase, the study achieved the primary endpoint: mean blood levels of alanine aminotransferase ("ALT"), a common biomarker for NASH, were reduced by over 50%. Additionally, over half of the study participants had achieved normalized ALT levels by the end of the treatment phase. There are no currently approved drug therapies for NASH. These interim results have established proof-of-concept and support further clinical development of DR Cysteamine in NASH.
The Company also announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco. The objective of the single center, double-blind, randomized study conducted by Mark Wallace, M.D., Professor of Clinical Anesthesiology at the Center for Pain Medicine of the University of California at San Diego, was to demonstrate that the orally administered prodrug NGX426, maintains the analgesic effect previously shown for the active moiety tezampanel. Using a cross-over design, a total of 18 study subjects received single doses of 90 mg of NGX426, 150 mg of NGX426 or placebo in each of three treatment periods. Pain was induced by injecting 250 ug of capsaicin between layers of skin in the forearm at 30 minutes and 120 minutes after dosing. This is yet another valuable asset in Raptor’s clinical pipeline. The Company plans to continue to explore options with NGX426 in the treatment of pain, which potentially include spinning-out or partnering this program to ensure that shareholders receive the maximum value from this potentially groundbreaking drug.
In addition, Raptor will potentially have their cystinosis drug on the market in 1H 2011. The fact that Raptor is potentially 18 months away from producing revenues represents a significant opportunity for investors and why we believe Raptor’s share price will increase substantially from current levels. Raptor currently has a balanced pipeline of clinical and preclinical programs. The Company is currently involved in four Phase II clinical programs. The Company’s clinical trials address indications representing large markets worldwide: ALDH2 deficiency and NASH; along with Orphan Indications which typically have a shorter development cycle: cystinosis, and Huntington’s Disease. ALDH2 deficiency and Huntington’s Disease each represent potentially billion dollar markets.
Target Price: $6.56 <<< Kursziel von Vista (ende Nov 2009)
Raptor announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.S. population.
the completion of the initial six-month treatment phase, the study achieved the primary endpoint: mean blood levels of alanine aminotransferase ("ALT"), a common biomarker for NASH, were reduced by over 50%. Additionally, over half of the study participants had achieved normalized ALT levels by the end of the treatment phase. There are no currently approved drug therapies for NASH. These interim results have established proof-of-concept and support further clinical development of DR Cysteamine in NASH.
The Company also announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco. The objective of the single center, double-blind, randomized study conducted by Mark Wallace, M.D., Professor of Clinical Anesthesiology at the Center for Pain Medicine of the University of California at San Diego, was to demonstrate that the orally administered prodrug NGX426, maintains the analgesic effect previously shown for the active moiety tezampanel. Using a cross-over design, a total of 18 study subjects received single doses of 90 mg of NGX426, 150 mg of NGX426 or placebo in each of three treatment periods. Pain was induced by injecting 250 ug of capsaicin between layers of skin in the forearm at 30 minutes and 120 minutes after dosing. This is yet another valuable asset in Raptor’s clinical pipeline. The Company plans to continue to explore options with NGX426 in the treatment of pain, which potentially include spinning-out or partnering this program to ensure that shareholders receive the maximum value from this potentially groundbreaking drug.
In addition, Raptor will potentially have their cystinosis drug on the market in 1H 2011. The fact that Raptor is potentially 18 months away from producing revenues represents a significant opportunity for investors and why we believe Raptor’s share price will increase substantially from current levels. Raptor currently has a balanced pipeline of clinical and preclinical programs. The Company is currently involved in four Phase II clinical programs. The Company’s clinical trials address indications representing large markets worldwide: ALDH2 deficiency and NASH; along with Orphan Indications which typically have a shorter development cycle: cystinosis, and Huntington’s Disease. ALDH2 deficiency and Huntington’s Disease each represent potentially billion dollar markets.
Die 2$ dürfte nächste Woche fallen .Das Potential ist enorm deshalb wird Raptor kein kurzfristiges Investment sein .
Raptor has a high quality, experienced management team that has seen two drugs go through the arduous clinical process to commercialization at a previous company .The Company’s CEO, Christopher M. Starr, Ph.D., was a founder of BioMarin Pharmaceutical Inc. and saw both Aldurazyme and Naglazyme go from preclinical studies to market approval and commercialization. Aldurazyme, BioMarin’s first approved drug, had revenues of $151.3 million in 2008 (net $72.5 million to BioMarin based on their partnership with Genzyme).Naglazyme, BioMarin’s second approved drug,had revenues of $132.7 million in 2008.BioMarin is currently a multi-billion dollar market cap company and we believe that Dr. Starr and his management and scientific team, most of them originally from BioMarin, can do it again with Raptor Pharmaceuticals Corp.
Raptor has a high quality, experienced management team that has seen two drugs go through the arduous clinical process to commercialization at a previous company .The Company’s CEO, Christopher M. Starr, Ph.D., was a founder of BioMarin Pharmaceutical Inc. and saw both Aldurazyme and Naglazyme go from preclinical studies to market approval and commercialization. Aldurazyme, BioMarin’s first approved drug, had revenues of $151.3 million in 2008 (net $72.5 million to BioMarin based on their partnership with Genzyme).Naglazyme, BioMarin’s second approved drug,had revenues of $132.7 million in 2008.BioMarin is currently a multi-billion dollar market cap company and we believe that Dr. Starr and his management and scientific team, most of them originally from BioMarin, can do it again with Raptor Pharmaceuticals Corp.
Bin auch mit von der Partie. Schauen wir mal was da noch so kommt. Bei IPCI bin ich auch dabei.
Verfolge deine Threads schon über einen längeren Zeitraum
und bin immer wieder erstaunt darüber wo Du das alles ausgräbst. In den meisten Fällen hatte es sich ja gelohnt für Dich. Respect für deine Arbeit.
Gruss und weiter so
B@rca
Verfolge deine Threads schon über einen längeren Zeitraum
und bin immer wieder erstaunt darüber wo Du das alles ausgräbst. In den meisten Fällen hatte es sich ja gelohnt für Dich. Respect für deine Arbeit.
Gruss und weiter so
B@rca
Antwort auf Beitrag Nr.: 38.701.406 von b@rca am 09.01.10 20:15:39Danke dir ..
--------
Man hat es schon geahnt das da was im busch ist , das dürfte reichen um über die 2$-Marke zu steigen .
11.01.2010 12:32
Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis
NOVATO, California, January 11 /PRNewswire/ --
- Potential to Improve Treatment with Less Frequent Administration and Better Tolerability
Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced the publication of results from a Phase 2a clinical trial of a prototype formulation of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). Ranjan Dohil, M.D., Professor of Pediatrics at the University of California, San Diego, was lead author of the study to be published in the Journal of Pediatrics and available online at http://www.ncbi.nlm.nih.gov/pubmed/19775699?itool=EntrezSyst…
(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO )
The Phase 2a study demonstrated proof-of-concept for DR Cysteamine, which is Raptor's proprietary, delayed-release, enteric-coated microbead formulation of immediate release cysteamine bitartrate contained in a gelatin capsule. Immediate-release cysteamine bitartrate ("IR Cysteamine") is the current standard of care for treating cystinosis. The results indicated that when given twice daily, the prototype DR Cysteamine formulation was effective at maintaining low white blood cell ("WBC") cystine levels (<2 nmol half-cystine/mg protein) in subjects with cystinosis. Results also indicated that the prototype DR Cysteamine effectively maintained trough WBC cystine levels within a satisfactory range when patients received approximately 60% of the previous total daily dose of IR Cysteamine.
Dr. Dohil stated, "We are seeking to improve tolerability and reduce dosing frequency requirements of IR Cysteamine which have been documented challenges for cystinosis patients, leading to widely reported instances of poor treatment compliance. We believe the results of the Phase 2a study bring us significantly closer to a potential treatment solution for cystinosis patients. The results from our trial indicate prototype delayed-release cysteamine formulation lead to improved tolerability and efficacy when administered twice-daily and at a lower total daily dose than IR Cysteamine. Based on these results, I believe that Raptor's final DR Cysteamine formulation has the potential to improve compliance and long-term treatment outcomes for cystinosis patients."
Based on these Phase 2a results, Raptor conducted a Phase 2b clinical trial using its final commercial formulation of DR Cysteamine and recently announced the following top-line Phase 2b results: DR Cysteamine demonstrated improved tolerability and the potential to reduce total daily dosage and administration frequency compared to IR Cysteamine.
- Pharmacokinetic evaluation showed that DR Cysteamine had a terminal half-life more than three times longer than the terminal half-life of IR Cysteamine. - Twice-daily DR Cysteamine may achieve the same pharmacodynamic result while using a total daily dose 30% lower than IR Cysteamine administered four times daily. - No adverse events recorded during the clinical trial were determined by the principal investigator to be possibly or probably related to DR Cysteamine. Nine adverse events recorded in the clinical trial were determined to be possibly or probably related to IR Cysteamine. - The proprietary, final formulation of DR Cysteamine confirmed earlier clinical trials conducted by Dr. Dohil using an enteric-coated prototype formulation of cysteamine bitartrate, which was funded by the Cystinosis Research Foundation ("CRF").
During the first quarter of 2010, Raptor plans to meet with the Food and Drug Administration ("FDA") and European Medicines Agency ("EMEA") to discuss plans for a repeat-dose, pivotal, Phase 3 clinical trial in cystinosis patients. Upon receiving FDA and EMEA agreements on protocol, Raptor intends to initiate its Phase 3 clinical trial at multiple sites in the US and Europe.
Cystinosis is an inborn metabolic error characterized by the abnormal transport of cystine, an amino acid, out of the lysosomes. Failure to treat cystinosis can cause serious health consequences, including renal failure and resultant kidney transplant, growth failure, rickets, photophobia and blindness. Symptom onset typically occurs within the first year of life, when cystine crystals accumulate in various tissues and organs, including the kidneys, brain, liver, thyroid, pancreas, muscles and eyes.
--------
Man hat es schon geahnt das da was im busch ist , das dürfte reichen um über die 2$-Marke zu steigen .
11.01.2010 12:32
Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis
NOVATO, California, January 11 /PRNewswire/ --
- Potential to Improve Treatment with Less Frequent Administration and Better Tolerability
Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced the publication of results from a Phase 2a clinical trial of a prototype formulation of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). Ranjan Dohil, M.D., Professor of Pediatrics at the University of California, San Diego, was lead author of the study to be published in the Journal of Pediatrics and available online at http://www.ncbi.nlm.nih.gov/pubmed/19775699?itool=EntrezSyst…
(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO )
The Phase 2a study demonstrated proof-of-concept for DR Cysteamine, which is Raptor's proprietary, delayed-release, enteric-coated microbead formulation of immediate release cysteamine bitartrate contained in a gelatin capsule. Immediate-release cysteamine bitartrate ("IR Cysteamine") is the current standard of care for treating cystinosis. The results indicated that when given twice daily, the prototype DR Cysteamine formulation was effective at maintaining low white blood cell ("WBC") cystine levels (<2 nmol half-cystine/mg protein) in subjects with cystinosis. Results also indicated that the prototype DR Cysteamine effectively maintained trough WBC cystine levels within a satisfactory range when patients received approximately 60% of the previous total daily dose of IR Cysteamine.
Dr. Dohil stated, "We are seeking to improve tolerability and reduce dosing frequency requirements of IR Cysteamine which have been documented challenges for cystinosis patients, leading to widely reported instances of poor treatment compliance. We believe the results of the Phase 2a study bring us significantly closer to a potential treatment solution for cystinosis patients. The results from our trial indicate prototype delayed-release cysteamine formulation lead to improved tolerability and efficacy when administered twice-daily and at a lower total daily dose than IR Cysteamine. Based on these results, I believe that Raptor's final DR Cysteamine formulation has the potential to improve compliance and long-term treatment outcomes for cystinosis patients."
Based on these Phase 2a results, Raptor conducted a Phase 2b clinical trial using its final commercial formulation of DR Cysteamine and recently announced the following top-line Phase 2b results: DR Cysteamine demonstrated improved tolerability and the potential to reduce total daily dosage and administration frequency compared to IR Cysteamine.
- Pharmacokinetic evaluation showed that DR Cysteamine had a terminal half-life more than three times longer than the terminal half-life of IR Cysteamine. - Twice-daily DR Cysteamine may achieve the same pharmacodynamic result while using a total daily dose 30% lower than IR Cysteamine administered four times daily. - No adverse events recorded during the clinical trial were determined by the principal investigator to be possibly or probably related to DR Cysteamine. Nine adverse events recorded in the clinical trial were determined to be possibly or probably related to IR Cysteamine. - The proprietary, final formulation of DR Cysteamine confirmed earlier clinical trials conducted by Dr. Dohil using an enteric-coated prototype formulation of cysteamine bitartrate, which was funded by the Cystinosis Research Foundation ("CRF").
During the first quarter of 2010, Raptor plans to meet with the Food and Drug Administration ("FDA") and European Medicines Agency ("EMEA") to discuss plans for a repeat-dose, pivotal, Phase 3 clinical trial in cystinosis patients. Upon receiving FDA and EMEA agreements on protocol, Raptor intends to initiate its Phase 3 clinical trial at multiple sites in the US and Europe.
Cystinosis is an inborn metabolic error characterized by the abnormal transport of cystine, an amino acid, out of the lysosomes. Failure to treat cystinosis can cause serious health consequences, including renal failure and resultant kidney transplant, growth failure, rickets, photophobia and blindness. Symptom onset typically occurs within the first year of life, when cystine crystals accumulate in various tissues and organs, including the kidneys, brain, liver, thyroid, pancreas, muscles and eyes.
Langsam aber sicher gehts weiter aufwärts ...
Mit den ganzen News die noch bevorstehen dürfte es locker richtung 5$ gehen ....
WntTideTM (Breast Cancer) Preclinical (ongoing) data to publish Q4 2009
DR Cysteamine Non-Alcoholic Steatohepatitis ("NASH") Phase IIa (ongoing, open IND), data Q4 09
DR Cysteamine Nephropathic Cystinosis (“Cystinosis”) Phase IIa (ongoing, open IND) Orphan Drug Designation, IIb ongoing, Phase III Q1 2010
DR Cysteamine Huntington’s Disease ("HD") Phase II (planned Q1 2010) Orphan Drug Designation
http://ih.advfn.com/p.php?pid=staticchart&s=N%5ERPTP&p=0&t=1…
WntTideTM (Breast Cancer) Preclinical (ongoing) data to publish Q4 2009
DR Cysteamine Non-Alcoholic Steatohepatitis ("NASH") Phase IIa (ongoing, open IND), data Q4 09
DR Cysteamine Nephropathic Cystinosis (“Cystinosis”) Phase IIa (ongoing, open IND) Orphan Drug Designation, IIb ongoing, Phase III Q1 2010
DR Cysteamine Huntington’s Disease ("HD") Phase II (planned Q1 2010) Orphan Drug Designation
http://ih.advfn.com/p.php?pid=staticchart&s=N%5ERPTP&p=0&t=1…
Nur ca 4000st trennen uns von der 3$ !!!!
Wir dürfen bald auf neue Partnerschaften hoffen ...
The Company is currently in the process of negotiating strategic partnerships and collaborations in order to fund its preclinical and clinical programs into 2011.
The Company is currently in the process of negotiating strategic partnerships and collaborations in order to fund its preclinical and clinical programs into 2011.
Antwort auf Beitrag Nr.: 38.746.542 von BrauchGeld am 15.01.10 16:42:21Klasse Teil. Läuft irgendwie wie geschmiert.
Step by step. Ohne grosse Sprünge - ohne Gaps.
Gut beackert "Brauch Geld"
Step by step. Ohne grosse Sprünge - ohne Gaps.
Gut beackert "Brauch Geld"
Antwort auf Beitrag Nr.: 38.748.939 von b@rca am 15.01.10 21:33:38Wir werden noch ein paar €´s mit Aktie einsacken ....
Neues Buy-Rating ..
With cash, the value of the pipeline increases considering the company can now move candidates forward. From Vista newsletter:
Raptor Pharmaceutical Corp. (RPTP)
Current Price: $1.95
Target Price: $5.55
Raptor announced that it completed its registered direct offering with institutional investors, raising an aggregate amount of approximately $7.5 million of gross proceeds (before placement agent fees and offering expenses) through the sale of 3,747,558 units. The units consist of one share of common stock and one warrant to purchase 0.5 of a share of common stock with a term of five years, and one warrant to purchase 0.5 of a share of common stock with a term of 18 months. Both warrants have an exercise price of $2.45 per share of common stock and are not exercisable for six months. This is highly encouraging news as the Company now has the necessary funds to move all of their clinical programs forward with a focus on DR Cysteamine, for the treatment of cystinosis. We believe the current sell off in the stock represents a tremendous buying opportunity considering the Company is approximately 12 months away from a potential FDA approval for DR cysteamine. We believe the company is worth at least $125M today based on our risk adjusted net present value calculation which is nearly 3 times the current share price. The value of the company will continue to increase with the continued advance of their clinical candidates.
Neues Buy-Rating ..
With cash, the value of the pipeline increases considering the company can now move candidates forward. From Vista newsletter:
Raptor Pharmaceutical Corp. (RPTP)
Current Price: $1.95
Target Price: $5.55
Raptor announced that it completed its registered direct offering with institutional investors, raising an aggregate amount of approximately $7.5 million of gross proceeds (before placement agent fees and offering expenses) through the sale of 3,747,558 units. The units consist of one share of common stock and one warrant to purchase 0.5 of a share of common stock with a term of five years, and one warrant to purchase 0.5 of a share of common stock with a term of 18 months. Both warrants have an exercise price of $2.45 per share of common stock and are not exercisable for six months. This is highly encouraging news as the Company now has the necessary funds to move all of their clinical programs forward with a focus on DR Cysteamine, for the treatment of cystinosis. We believe the current sell off in the stock represents a tremendous buying opportunity considering the Company is approximately 12 months away from a potential FDA approval for DR cysteamine. We believe the company is worth at least $125M today based on our risk adjusted net present value calculation which is nearly 3 times the current share price. The value of the company will continue to increase with the continued advance of their clinical candidates.
!
Dieser Beitrag wurde moderiert. Grund: Postings von Doppel-IDs
Mit etwas glück sehen wir schon diese Woche die 3$ ....
Bald gibts News dann ist es vorbei mit den kleinen Schritten nach oben ....
Shares Outstanding: 22.58 M
Float: 7.84 M
http://seekingalpha.com/article/182956-raptor-pharma-ceo-sta…
Shares Outstanding: 22.58 M
Float: 7.84 M
http://seekingalpha.com/article/182956-raptor-pharma-ceo-sta…
Antwort auf Beitrag Nr.: 38.808.117 von BrauchGeld am 25.01.10 19:49:29Hätte ich nichts dagegen. Aber so ist es ja auch nicht schlecht. Man hat sich schon daran gewöhnt ständig im Plus zu enden. Bin mal gespannt auf die nächsten News. Könnte die Bekanntgabe des neuen Vetriebspartner sein.
Antwort auf Beitrag Nr.: 38.809.009 von b@rca am 25.01.10 21:48:21Und wir wissen das der CEO da sehr gute kontakte hat wird also bestimmt ein guter Deal ...
In den nächsten 8 Wochen ist mit einigen News zurechnen ...
DR Cysteamine Nephropathic Cystinosis (“Cystinosis”) Phase IIa (ongoing, open IND) Orphan Drug Designation, IIb ongoing, Phase III Q1 2010
DR Cysteamine Huntington’s Disease ("HD") Phase II (planned Q1 2010) Orphan Drug Designation
DR Cysteamine Nephropathic Cystinosis (“Cystinosis”) Phase IIa (ongoing, open IND) Orphan Drug Designation, IIb ongoing, Phase III Q1 2010
DR Cysteamine Huntington’s Disease ("HD") Phase II (planned Q1 2010) Orphan Drug Designation
Raptor Pharmaceutical Corp. to Present Cystinosis Research at Lysosomal Disease Network's 2010 WORLD Symposium
http://www.finanznachrichten.de/nachrichten-2010-02/16110991…
http://www.finanznachrichten.de/nachrichten-2010-02/16110991…
Vista Partners gibt für Raptor ein 12-Monatskursziel von 5,55 US-Dollar aus. Am Markt wird dies kaum zur Kenntnis genommen.
Originalmeldung:
LOS ANGELES, Feb 11, 2010 /PRNewswire via COMTEX/ -- Vista Partners announced today that it has updated coverage on Raptor Pharmaceutical Corp. and raised its split adjusted twelve month target price to $5.55. Ross Silver, Principal Analyst for Vista Partners stated, "Raptor's current valuation is well below its peer group which does not make a lot of sense considering Raptor is currently involved in five Phase II clinical programs with some indications in multi-billion dollar markets. The recently closed $7.5M equity offering will enable the Company to move all of their principal clinical programs forward, with a primary focus on their lead compound, DR Cysteamine, for the treatment of cystinosis." Mr. Silver continued, "With a strong balance sheet, robust clinical pipeline and management team that has taken compounds from concept to approval twice already, we believe Raptor should trade at a premium to their peer group and as such we anticipate significant share price appreciation in 2010." For more information and to download the report for FREE, please visit the Vista Partners website at www.vistap.com and click on the "download research" icon or click here.
Originalmeldung:
LOS ANGELES, Feb 11, 2010 /PRNewswire via COMTEX/ -- Vista Partners announced today that it has updated coverage on Raptor Pharmaceutical Corp. and raised its split adjusted twelve month target price to $5.55. Ross Silver, Principal Analyst for Vista Partners stated, "Raptor's current valuation is well below its peer group which does not make a lot of sense considering Raptor is currently involved in five Phase II clinical programs with some indications in multi-billion dollar markets. The recently closed $7.5M equity offering will enable the Company to move all of their principal clinical programs forward, with a primary focus on their lead compound, DR Cysteamine, for the treatment of cystinosis." Mr. Silver continued, "With a strong balance sheet, robust clinical pipeline and management team that has taken compounds from concept to approval twice already, we believe Raptor should trade at a premium to their peer group and as such we anticipate significant share price appreciation in 2010." For more information and to download the report for FREE, please visit the Vista Partners website at www.vistap.com and click on the "download research" icon or click here.
Antwort auf Beitrag Nr.: 38.933.668 von fernandopessoa am 12.02.10 12:57:43Bald gibts News dann wird die Aktie schon steigen ...
Bin auch seit Anfang 2010 dabei. Gutes Ding.
Der gestrige Handel in den USA war für Raptor interessant. Keine Nachrichten, aber mit dem Kurs ging es bei einem leicht erhöhten Handelsvolumen nach oben. Ich denke, die Charttechnik können wir hier vernachlässigen. Auch wenn diese ganz gut aussieht. Was wir brauchen, sind News und Aufmerksamkeit. An beiden mangelt es derzeit noch. Gestern könnte aber ein Anfang gewesen sein...
Frisch aus der "Tickerpresse":
Raptor Pharmaceutical Announces Publication of Data Supporting Potential Efficacy of WntTide(TM) in Treatment of Triple-Negative Breast Cancer
Hier geht es zur ausführlichen Originalmeldung:
http://ir.raptorpharma.com/phoenix.zhtml?c=198466&p=irol-new…
So, sind Mediziner an Board? Dann bitte ich um eine Deutung!
Raptor Pharmaceutical Announces Publication of Data Supporting Potential Efficacy of WntTide(TM) in Treatment of Triple-Negative Breast Cancer
Hier geht es zur ausführlichen Originalmeldung:
http://ir.raptorpharma.com/phoenix.zhtml?c=198466&p=irol-new…
So, sind Mediziner an Board? Dann bitte ich um eine Deutung!
gibts irgendwelche Gründe warum die so abschmiert in den letzten Tagen? von 1,80 auf 1,26 € runter über 40%
Raptor Pharmaceutical Announces Engagement of The Trout Group for Strategic Management of Investor Relations
http://www.globenewswire.com/newsroom/news.html?ref=rss&d=18…
http://www.globenewswire.com/newsroom/news.html?ref=rss&d=18…
Antwort auf Beitrag Nr.: 39.286.739 von watchi am 07.04.10 13:17:49hoffe diese nachricht erweckt Raptor aus dem tiefschlaf...
kursvolumen hat deutlich abgenommen...
potential ist ja doch in erheblichem maße vorhanden;
die firma geht ja straight ihren weg nach vorn -
ich sehe hier erhebliches potential obwohl der
titel total aus dem us-biotech radar verschwunden ist -
ich werde halten
kursvolumen hat deutlich abgenommen...
potential ist ja doch in erheblichem maße vorhanden;
die firma geht ja straight ihren weg nach vorn -
ich sehe hier erhebliches potential obwohl der
titel total aus dem us-biotech radar verschwunden ist -
ich werde halten
premarket-umsätze hatten wir auch schon lange nicht mehr...
aber wehe es gibt wieder ein "billiges financing"
aber wehe es gibt wieder ein "billiges financing"
jetzt müsste doch bald mal ein Boden erreicht sein...
Wie weit soll sie denn noch fallen?
Wie weit soll sie denn noch fallen?
sehr ruhig hier geworden - umsätze und kurs ziehen jedoch wieder
deutlich an...p3 sollte im 1.quartal gestartet werden...
hab noch nichts darüber gelesen -sollte bald news kommen
deutlich an...p3 sollte im 1.quartal gestartet werden...
hab noch nichts darüber gelesen -sollte bald news kommen
Antwort auf Beitrag Nr.: 39.431.833 von Gustl24 am 30.04.10 11:24:31und da ist die news schon - war an den umsätzen
letzter woche klar absehbar
Raptor Pharmaceutical Announces Phase 2a NASH Study Meets Primary Endpoints: Results Released at Digestive Disease Week Conference
May 3, 2010 (GlobeNewswire via COMTEX) --
Statistically Significant Results With 64% of Patients Showing > 50%
Reduction in ALT and AST Levels and 55% Achieving Normal Levels
letzter woche klar absehbar
Raptor Pharmaceutical Announces Phase 2a NASH Study Meets Primary Endpoints: Results Released at Digestive Disease Week Conference
May 3, 2010 (GlobeNewswire via COMTEX) --
Statistically Significant Results With 64% of Patients Showing > 50%
Reduction in ALT and AST Levels and 55% Achieving Normal Levels
sonderbar - keiner mehr am start
raptor heute einer der tagesgewinner...bin mit guten gewinnen
jetzt raus...etwas zu früh wie es scheint, aber doch sehr einträglich!!
viel erfolg den investierten weiterhin!
raptor heute einer der tagesgewinner...bin mit guten gewinnen
jetzt raus...etwas zu früh wie es scheint, aber doch sehr einträglich!!
viel erfolg den investierten weiterhin!
Alles stille Geniesser! 
Raptor Pharmaceutical's DR Cysteamine Receives Orphan Medicinal Product Designation From the European Medicines Agency
http://www.finanznachrichten.de/nachrichten-2010-06/17157291…
http://www.finanznachrichten.de/nachrichten-2010-06/17157291…
Jetzt sollte es noch mal einen schönen Schub geben!
Nachdem wir die letzten Wochen 20% abgegeben haben, kann da einiges passieren.
Nachdem wir die letzten Wochen 20% abgegeben haben, kann da einiges passieren.
Welcher Knackhansel schmeißt denn da in Fra.? 
Antwort auf Beitrag Nr.: 39.685.728 von watchi am 15.06.10 17:31:41
Der wird sich jetzt ärgern.
Drüben gestern gegen Ende 10% hochgeschnellt, und hier kennt kaum einer den Wert...
Der wird sich jetzt ärgern.Drüben gestern gegen Ende 10% hochgeschnellt, und hier kennt kaum einer den Wert...
bin am überlegen jetzt noch in diesen wert einzusteigen.
würde einer der schon investierten und besser informierten doch mal kurz anreißen, wie es um die firma steht, ob es sich noch lohnt einzusteigen zu diesen kursen und wie das mögliche potential ist.
würde einer der schon investierten und besser informierten doch mal kurz anreißen, wie es um die firma steht, ob es sich noch lohnt einzusteigen zu diesen kursen und wie das mögliche potential ist.
Tach!
Mal zum Vergleich (s. Eröffnungsposting):
Mal zum Vergleich (s. Eröffnungsposting):
Positive News für Raptor ....
War mir schon immer klar das Raptor eine Perle ist leider hab ich die etwas zu früh abgestossen .
Raptor Pharmaceutical Meets Primary Endpoint in Its Phase 3 Clinical Trial of DR Cysteamine for Nephropathic Cystinosis
Raptor Pharmaceutical Meets Primary Endpoint in Its Phase 3 Clinical Trial of DR Cysteamine for Nephropathic Cystinosis
Raptor Pharmaceutical Corp.
25.07.2011 12:30
http://www.finanznachrichten.de/nachrichten-2011-07/20879374…
War mir schon immer klar das Raptor eine Perle ist leider hab ich die etwas zu früh abgestossen .
Raptor Pharmaceutical Meets Primary Endpoint in Its Phase 3 Clinical Trial of DR Cysteamine for Nephropathic Cystinosis
Raptor Pharmaceutical Meets Primary Endpoint in Its Phase 3 Clinical Trial of DR Cysteamine for Nephropathic Cystinosis
Raptor Pharmaceutical Corp.
25.07.2011 12:30
http://www.finanznachrichten.de/nachrichten-2011-07/20879374…
Hmmm...ja. So gut, das es drüben gleich 20% runterknallt .... 
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,14 | |
| 0,00 | |
| -0,59 | |
| -2,29 | |
| -7,92 | |
| +0,42 | |
| +0,88 | |
| +2,05 | |
| +3,35 | |
| -3,85 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 198 | ||
| 95 | ||
| 70 | ||
| 51 | ||
| 46 | ||
| 45 | ||
| 43 | ||
| 41 | ||
| 34 | ||
| 27 |
